BioCryst Pharmaceuticals Strikes $70M European Licensing Deal

By Chris Stiles • Monday, May 04 12:00 • Permanent Link

BioCryst Pharmaceuticals said it struck a European licensing deal for navenibart that brings in $70 million upfront and could add as much as $275 million more in regulatory and sales milestones, plus royalties of 18% to 30% on net sales.

The agreement gives an Irish affiliate of Neopharmed Gentili exclusive rights to commercialize navenibart for hereditary angioedema in Europe. BioCryst said the deal builds on its earlier 2025 agreement to sell the European Orladeyo business to Neopharmed Gentili.

BioCryst’s navenibart phase 3 program remains on track for a U.S. regulatory filing by the end of 2027.

The company said the transaction strengthens its balance sheet while leaving it with milestone and royalty upside. It also said commercial responsibilities will now be split geographically, with BioCryst leading in the U.S. and Neopharmed Gentili handling Europe. The market has reacted to these announcements by moving the company's shares 2.06% to a price of $8.94. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.